Business Context and Reporting Period
This Form 8-K, dated March 13, 2015, reports a material definitive agreement entered into by Ruthigen, Inc. (the "Company") and Pulmatrix, Inc. The filing details a proposed merger where Ruthigen Merger Corp., a wholly-owned subsidiary of Ruthigen, will merge with and into Pulmatrix. Upon completion, Pulmatrix will become a wholly-owned subsidiary of Ruthigen, and Pulmatrix stockholders are expected to own approximately 81% of the combined entity's outstanding capital stock.
Key Financial Metrics and Transaction Terms
- Exchange Ratio: Each outstanding share of Pulmatrix common stock will convert into approximately 0.1482 shares of Ruthigen common stock.
- Cash Requirement: Ruthigen must maintain at least $9,000,000 in cash on hand as of the execution date, subject to reduction if closing occurs after July 31, 2015, or if audited financial statements are not provided by deadlines.
- Private Placement: Pulmatrix is required to secure a private placement of common stock and warrants for gross proceeds of $10,000,000 prior to closing.
- Debt Assumption: Ruthigen will assume Pulmatrix's outstanding bridge loan of $4,500,000, which will be converted into Ruthigen common stock at $2.75 per share.
- Escrow: 5,850,000 shares of Ruthigen common stock will be held in escrow for 12 months post-closing to cover potential indemnification claims.
- Executive Compensation: Ruthigen's CEO and CFO will receive lump sum termination payments of $547,600 and $337,500, respectively, plus restricted stock units and hourly fees for transition services.
Material Changes and Operational Adjustments
Until the merger is effective, Ruthigen is permitted to scale down its operations, including pausing patient enrollment in its Phase 1/2 clinical trials for RUT58-60. To meet the required cash amount, Ruthigen may sell up to 948,555 shares of its common stock at a price not less than $2.75 per share. Additionally, the Company consented to the sale of up to 400,000 shares of its common stock held by its former parent, Oculus Innovative Sciences, Inc., prior to the merger's effectiveness.
Guidance, Outlook, and Risks
The merger is subject to several conditions, including stockholder approval from both companies, the effectiveness of a registration statement on Form S-4, and the consummation of the $10,000,000 private placement. The agreement may be terminated if the merger is not consummated by August 13, 2015, if a court injunction is issued, or if requisite stockholder approval is not obtained. A non-breaching party may terminate for uncured breaches and recover professional fees up to $100,000. Post-merger, the Board of Directors will be comprised of persons selected by Pulmatrix, subject to Ruthigen's consent.
Investor Verification Checklist
- Verify the final exchange ratio and the percentage of ownership Pulmatrix stockholders will hold post-merger.
- Confirm the status of the $10,000,000 private placement required for Pulmatrix prior to closing.
- Monitor Ruthigen's cash position to ensure it meets the $9,000,000 threshold or any adjusted requirements.
- Review the terms of the $4,500,000 bridge loan conversion and its impact on share dilution.
- Check for updates on the Form S-4 registration statement and stockholder approval votes.
- Assess the impact of the scaled-down clinical trials on Ruthigen's standalone business value if the merger fails.